Drugs / TGM-312-SC01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07427680 | Mar 2026 → Mar 2028 expected | metabolic dysfunction-associated steatohepatitis | Tangram Therapeutics Plc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGM-312-SC01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07427680 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT07427680 ↗ |